ASAvinash Kumar Singh

Avinash Kumar Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Avinash Kumar Singh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nanofiber-Driven Approaches in Tissue Engineering and Regenerative Medicine

    by Arya Vidyadhari, Avinash Kumar Singh

    Nanofiber, a novel approach in tissue engineering and regenerative medicine, emphasizes versatility in structure, drug entrapment capabilities, and advanced fabrication techniques that architect a biomimetic scaffold which supports tissue repair and regeneration. Due to the extensive surface area, controlled porosity, adherence to the cells and correspondence with the biological scaffold, nanofiber involves itself in optimal cell proliferation and differentiation. This nanofiber-driven approach prospects other designing methods (such as electrospinning), surface modification, and the incorporation of active ingredients to improve therapeutic responses. The promising objective for the management of healing wounds, bone and cartilage regeneration, normal tissue engineering, and advanced drug delivery emerges as the translational approach of nanofiber mats in novel regenerative medicine.

  • Open Access

    Prevalence of anemia among chronic myeloid leukemia patients treated with Imatinib: A evidence based meta-analysis.

    by Avinash Singh, Anoop Kumar, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed, Manju Sharma

    Aim- Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear. The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib. Methods- The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st January 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% C. I was calculated using StatsDirect Statistical analysis software V.3. Results A total of 18 studies containing 3,537 patients (male-1912 and female-1478) were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion: The physician should also take care of anemia while treating CML patients with imatinib. Anemia is a major concern associated with CML patients treated with Imatinib.

  • Open Access

    Drug-loaded electrospun nanofiber for Vulvovaginal candidiasis: A systematic literature review

    by Arya Vidyadhari, Avinash Kumar Singh, Tanya Ralli, Suhel Parvez, Kanchan Kohli


  • Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients

    by Avinash Kumar Singh, Arya Vidyadhari, Dinesh Bhurani, Narendra Agrawal, Rayaz Ahmed, Manju Sharma

    Purpose: In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia. Methods: The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22. Results: In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05). Conclusion: We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.


  • Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience

    by Avinash Kumar Singh, Mohammad Azharuddin, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed, Manju Sharma

  • Open Access

    Role of colchicine in the management of COVID-19 patients: A meta-analysis of cohort and randomized controlled trials

    by Avinash Kumar Singh, Arya Vidyadhari, Harmandeep Singh, Kashif Haider, Anoop Kumar, Manju Sharma


  • Open Access

    Assessment of Patients Health-Related Quality of Life During Complications of Pregnancy in a Tertiary Care Teaching Hospital: a Prospective Study

    by Vartika Jain, Avinash Kumar Singh

    Background and Objective: Pregnancy has undesirable effects on women lives which lead to reduction in quality of life. Assessment of Quality of Life is necessary among pregnant women because of association with the various complications. Hence, the present study was conducted to evaluate the patient’s health-related quality of life during complications of pregnancy. Method: A prospective observational single centered study was conducted on 81 pregnant women who were diagnosed with complications (Anemia, UTI, Pre-eclampsia and Hyperemesis gravid arum) in Obstetrics & Gynecology department of NIMS Hospital, Jaipur, (Rajasthan). Result: The mean score of physical component scale (PCS) and mental component scale (MCS) was found to be 58.43±0.70 and 75.8±1.25 respectively. The mean score at the time of discharge were physical functioning 69.8±13.77, role limitation due to physical problems 79.01±16.15, role limitation due to emotional problems 68.00±17.10, vitality 48.68±7.30, mental health 98.64±4.25, social functioning 87.22±18.71, bodily pain 80.61±12.67, general health 72.5±4.06 and reported health transition 82.71±12.89 and overall score at p-value was found to be significant. Conclusion: HRQoL of pregnant women associated with complications has been improved where mental health tends to recover more quickly than physical health. Keywords: Quality of Life; Anemia; UTI; Pre-eclampsia; Hyperemesis gravidarum.

  • Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients

    by Avinash Kumar Singh, Salman Hussain, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani, Miloslav Klugar, Manju Sharma

    Background: Recently, multiple epidemiological studies have linked imatinib with the alteration of renal function in chronic myeloid leukaemia (CML) patients. This meta‐analysis aimed to summarize the impact of imatinib use on renal function in CML patients.Methods: A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle‐Ottawa scale (NOS). Two authors independently performed literature‐screening, risk of bias and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the grading of recommendations assessment, development and evaluation (GRADE) criteria.Results: A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta‐analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p < .05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (chronic kidney disease or acute kidney injury) was found to be significantly higher in imatinib users as compared to other tyrosine kinase inhibitor (TKI) users with a pooled relative risk of 2.70 (95% CI: 1.49–4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence.Conclusion: This meta‐analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.